Stephen R. Foley

Hamilton, ON, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 18, 2025

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.

Journal: Journal for immunotherapy of cancer
Published: January 11, 2025

Cross-linked chitosan as biomacromolecular adsorbents for adsorption of precious metal-chloride complexes from aqueous media.

Cross-linked chitosan as biomacromolecular adsorbents for adsorption of precious metal-chloride complexes from aqueous media.

Journal: International journal of biological macromolecules
Published: July 02, 2024

An Overview of Modified Chitosan Adsorbents for the Removal of Precious Metals Species from Aqueous Media.

An Overview of Modified Chitosan Adsorbents for the Removal of Precious Metals Species from Aqueous Media.

Journal: Molecules (Basel, Switzerland)
Published: December 31, 2021

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.

Journal: Blood advances
Published: October 04, 2021

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

Journal: The Lancet. Oncology
Published: April 06, 2021

Autologous, lentivirus-modified, T-rapa cell "micropharmacies" for lysosomal storage disorders.

Autologous, lentivirus-modified, T-rapa cell "micropharmacies" for lysosomal storage disorders.

Journal: EMBO molecular medicine
Published: March 18, 2021

Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma.

Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma.

Journal: Cytotherapy
Published: January 31, 2021

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

Journal: Blood advances
Published: November 23, 2020

Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors.

Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors.

Journal: RSC medicinal chemistry
Published: January 08, 2020

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.

Journal: Blood advances
Published: September 24, 2019

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.

Journal: Blood advances
Published: May 31, 2019
Showing 1-12 of 16

Last Updated: 09/26/2026